Pentosan Polysulfate

Joint Health / Disease-Modifying Compoundapproved

Also known as: PPS, Cartrophen, Elmiron, Pentosan Polysulfate Sodium, NaPPS

A semi-synthetic polysaccharide (heparin-like compound) used clinically for interstitial cystitis and osteoarthritis, with disease-modifying effects on cartilage, joints, and the glycosaminoglycan layer.

Overview

Pentosan polysulfate sodium (PPS) is a semi-synthetic, low-molecular-weight heparin-like polysaccharide derived from beechwood hemicellulose. While technically not a peptide, it is frequently included in peptide clinic protocols for joint health. PPS is FDA-approved as Elmiron for interstitial cystitis (IC) / painful bladder syndrome and is widely used in veterinary medicine (as Cartrophen Vet) for osteoarthritis in dogs and horses. It acts as a disease-modifying osteoarthritis drug (DMOAD) by stimulating cartilage matrix synthesis, inhibiting cartilage-degrading enzymes, and improving synovial fluid quality. PPS also has fibrinolytic, anti-inflammatory, and lipid-clearing properties. In recent years, concerns have emerged about a potential association between long-term oral PPS use and a unique pigmentary maculopathy of the retina, prompting FDA warnings and renewed scrutiny of its risk-benefit profile.

Mechanism of Action

PPS acts through multiple pathways: (1) Stimulates proteoglycan and hyaluronic acid synthesis by chondrocytes and synoviocytes; (2) Inhibits matrix metalloproteinases (MMPs) and aggrecanases that degrade cartilage; (3) Restores the glycosaminoglycan (GAG) layer on the bladder urothelium in IC; (4) Inhibits complement activation and inflammatory cascades; (5) Has mild fibrinolytic activity, improving microcirculation in joint tissues; (6) Reduces subchondral bone remodeling; (7) Improves synovial fluid viscosity and joint lubrication; (8) Inhibits histamine release from mast cells.

Molecular Formula

Complex polysaccharide — average MW ~4,000-6,000 Da

Molecular Weight

4000-6000 Da (average)

Sequence

N/A — semi-synthetic polysaccharide, not a peptide

Dosage Protocols

Dose Range

100mg100mg

Frequency

Three times daily

Route

oral

Cycle Length

3-6 months initial trial; ongoing if effective

FDA-approved dose. Take 1 hour before or 2 hours after meals on empty stomach. Response may take 3-6 months. Oral bioavailability is low (~3%).

Source: FDA-approved prescribing information (Elmiron)

Side Effects

EffectSeverity
GI upsetmild
Headachemild
Hair loss (alopecia)moderate
Easy bruisingmild
Pigmentary maculopathysevere

Pros & Cons

FDA-approved with decades of clinical use and extensive safety data

Disease-modifying for osteoarthritis — not just symptomatic relief but actual cartilage protection

Injectable form provides much higher bioavailability and faster onset than oral

Multi-mechanism action on joints: stimulates repair, inhibits degradation, reduces inflammation

Risk of pigmentary maculopathy with long-term oral use — requires ophthalmologic monitoring

Very low oral bioavailability (~3%) limits effectiveness of approved oral route

Injectable form not FDA-approved for human use — requires off-label prescribing

Mild anticoagulant effects contraindicate use with blood thinners

Research Studies

Legal Status

FDA-approved as Elmiron (oral) for interstitial cystitis. Available by prescription. Injectable forms available in veterinary medicine (Cartrophen) and off-label human use from compounding pharmacies. Widely used in Australian and European medicine.

Related Peptides